DMAAR · Drugs Made In America Acquisition Corp. Ordinary Shares

Shareholders of Drugs Made in America Acquisition Corp. voted overwhelmingly to approve the Extension Proposal at the Extraordinary General Meeting on April 27, 2026, with approximately 79% of votes in favor (18.9 million FOR vs. 4.9 million AGAINST), meeting the special resolution threshold. This amends Article 48.7 and 48.8 of the Second Amended and Restated Memorandum and Articles, pushing the Termination Date from April 29, 2026, to potentially April 29, 2027, via up to 12 monthly extensions. Each extension requires the sponsor to deposit the lesser of $300,000 or $0.04 per non-redeemed public share into the Trust Account, providing critical runway for identifying and completing a business combination. The high redemption rate of 9.44 million shares (about 40% of outstanding shares as of record date) reflects significant shareholder exercise of redemption rights, reducing Trust Account funds by $99.3 million at $10.52 per share and leaving 24.3 million shares outstanding. This post-IPO share count of 13.6 million indicates sponsor and insider holdings remain intact. The Board's immediate approval of the first extension to May 29, 2026, signals commitment to the process. Investors should note the ongoing need for monthly sponsor contributions to sustain extensions, tying Company viability to sponsor funding amid redemption pressures.